CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 13 enrolled
Drug / intervention
itraconazoledrug
Likely dose
itraconazole 200mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00798135
NCT00798135N/ACompleted
CompareCT.gov

A Pilot Trial of Itraconazole Pharmacokinetics in Patients With Metastatic Breast Cancer

Indiana University·interventional·Posted Nov 25, 2008·Updated Dec 21, 2023

In Brief

A clinical study evaluating itraconazole for Breast Neoplasms and Neoplasm Metastasis. Completed, enrolled 13 participants across 1 site.

Detailed Summary

Cancer cells need to be able to make new blood vessels in order to keep growing. This is called angiogenesis. In a laboratory setting, the drug itraconazole was shown to help stop the growth of new blood vessels (anti-angiogenesis). It is hoped that itraconazole will prevent new blood vessels from forming in humans too. The purpose of this study is to look at how the body processes and breaks down itraconazole (called pharmacokinetics). This study will also measure markers in your blood to see if itraconazole stops new blood vessels from forming. The safety of itraconazole will also be tested to see what effects (good and bad) it has on you and your breast cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Neoplasms, Neoplasm Metastasis
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 25, 2008
Enrollment StartNov 1, 2008
Primary CompletionFeb 1, 2012
Study CompletionMar 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 17.6 years ago

Interventions

itraconazoledrug

oral itraconazole 200mg a day until disease progression or unacceptable toxicities.